Skip to main content
SpringerLink
Log in

Neue Therapiemöglichkeiten bei Vorhofflimmern

Schlaganfallrisiko minimieren

  • FORTBILDUNG
  • ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Aufgrund der demografischen Entwicklung muss mit einer Verdoppelung der Prävalenz von nicht valvulärem Vorhofflimmern (VHF) in den nächsten 30 Jahren gerechnet werden [2]. Zur Prävention von Schlaganfällen und systemischen Thrombembolien stehen jetzt neue orale Antikoagulanzien zur Verfügung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbildung 1

Literatur

  1. Stewart S et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90:286–92.

    Article  PubMed  CAS  Google Scholar 

  2. Miyasaka Y et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119–25.

    Article  PubMed  Google Scholar 

  3. Lloyd-Jones DM, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042–6.

    Article  PubMed  Google Scholar 

  4. Fuster V, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114:e257–354.

    Article  PubMed  Google Scholar 

  5. Marini C, et al. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke Results From a Population-Based Study Stroke 2005; 36:1115–9.

    Article  PubMed  Google Scholar 

  6. Lin HJ, et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke 1996; 27:1760–4

    Article  PubMed  CAS  Google Scholar 

  7. A. John Camm et al. Guidelines fort the management of atrial fibrillation. European Heart Journal (2010) 31, 2369–2429

    Article  PubMed  Google Scholar 

  8. Connolly S. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–1912.

    Article  PubMed  CAS  Google Scholar 

  9. Stahrenberg et. al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 2010 Dec;(41(12):2884–8

    Article  PubMed  Google Scholar 

  10. Gage BF et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–2870.

    Article  PubMed  CAS  Google Scholar 

  11. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263–272

    Article  PubMed  Google Scholar 

  12. Jörgensen et al. Acute stroke with atrial fibrillation, The Copenhagen Stroke Study. Stroke 1996; 27:1765–1769

    Article  PubMed  Google Scholar 

  13. Hart RG, et al. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–867.

    PubMed  Google Scholar 

  14. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study (SPAF). Circulation 1991, 84:527–539

    Article  Google Scholar 

  15. Fuster et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation. 2006; 114: 700–752

    Article  Google Scholar 

  16. Mant J et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503.

    Article  PubMed  CAS  Google Scholar 

  17. Brian F Gage et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. The American Journal of Medicine (2005) 118, 612–617

    Article  Google Scholar 

  18. Pisters R et.al. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; March 18 [Epubahead of print].

  19. Connolly et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361:1139–1151

    Article  PubMed  CAS  Google Scholar 

  20. A. John Camm. The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: Dabigatran vs. warfarin. European Heart Journal doi:10.1093/eurheartj/ehp384

  21. Graeme J.et al. Dabigatran Etexilate: A New Oral Thrombin Inhibitor. Circulation 2011;123;1436–1450

    Article  Google Scholar 

  22. Rocket AF Sudy Investigators. Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation N Engl J Med 2011; 365:883–891

    Article  Google Scholar 

  23. Erenberg et al.. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects. Published online before print September 6, 2011, doi: 10.1161

  24. Conolly et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2011; 364:806–817

    Article  Google Scholar 

  25. Granger et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981–92.

    Article  PubMed  CAS  Google Scholar 

  26. David R. Holmes et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised noninferiority trial. Lancet 2009;374:534–542.

    Article  PubMed  CAS  Google Scholar 

  27. Weber et al. Prevention of cardioembolic stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 2010, 8: 1405–1415

    Article  PubMed  Google Scholar 

  28. Sander et al. Primärprävention des Schlaganfalls-Was ist neu. Aktuelle Neurologie 2011; 38:414–427

    Article  Google Scholar 

  29. Terasawa et al. Systematic Review: Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation. Annals of Internal Medicine August 4, 2009 vol. 151 no. 3 191–202

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kinder-und Jugendpsychiatrie/Psychotherapie, Neurologische Klinik, Klinikum Ingolstadt, Krumenauer Str. 25, D-85049, Ingolstadt, Deutschland

    Rainer Dabitz

  2. Ingolstadt, Deutschland

    Günter Ochs

Authors
  1. Rainer Dabitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Günter Ochs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer Dabitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dabitz, R., Ochs, G. Neue Therapiemöglichkeiten bei Vorhofflimmern. MMW - Fortschritte der Medizin 154, 53–57 (2012). https://doi.org/10.1007/s15006-012-1346-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-012-1346-y

Keywords - Stroke risk — atrial fibrillation

Search

Navigation